Enzaplatovir

Drug Profile

Enzaplatovir

Alternative Names: BTA C585; BTA585

Latest Information Update: 14 Feb 2017

Price : $50

At a glance

  • Originator Biomolecular Research Institute; Biota Holdings
  • Developer Aviragen Therapeutics
  • Class Antivirals; Small molecules
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 01 Feb 2017 Top-line efficacy, pharmacokinetics and adverse events data from a phase IIa trial in Respiratory syncytial virus infections released by Aviragen Therapeutics
  • 01 Dec 2016 Aviragen Therapeutics completes a phase-II trial in Respiratory syncytial virus infections (In volunteers) in United Kingdom (PO) (NCT02718937)
  • 26 Oct 2016 Interim adverse events and pooled data analysis from phase I trials in Respiratory syncytial virus infections released by Aviragen Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top